Dunn Gordon's Form 4 filing
Quoin Pharmaceuticals Ltd. (QNRX) · filed Sep 11, 2024
- Accession no.
- 0001104659-24-098940
- Filed
- Sep 11, 2024
- Trade date
- Sep 9-10, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions. Open-market purchases total $23.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dunn GordonCIK 0001958139 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 9, 2024 | Ordinary Shares | PPurchaseAcquired | +856 | $0.80 | +$684.8 | 856 | Direct | |
| Sep 9, 2024 | Ordinary Shares | PPurchaseAcquired | +4,000 | $0.78 | +$3,120 | 4,856 | Direct | |
| Sep 9, 2024 | Ordinary Shares | PPurchaseAcquired | +4,000 | $0.80 | +$3,200 | 8,856 | Direct | |
| Sep 10, 2024 | Ordinary Shares | PPurchaseAcquired | +10,000 | $0.91 | +$9,100 | 18,856 | Direct | |
| Sep 10, 2024 | Ordinary Shares | PPurchaseAcquired | +10,000 | $0.71 | +$7,100 | 28,856 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.